Buyout fund research profile
Advent International has built a local India private-equity practice around control and complex growth situations in consumer, lending, manufacturing, pharmaceuticals and technology services. Shweta Jalan leads the India team, which pairs local execution with Advent’s global operating resources.
At a glance
Research profile
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
Advent International (India) uses a buyout approach across Health, pharma, fin services, industrial.
Current evidence
Advent’s India page and portfolio story document the 2024 sale of Bharat Serums and Vaccines to Mankind after operational improvements, including a reported EBITDA uplift during ownership; the India team page remains current with Shweta Jalan identified as Managing Partner.
Strategy
Buyout
Sector focus
Health, pharma, fin services, industrial
AIF structure context
Indian private equity, growth, buyout and many real-asset strategies are commonly structured as Category II AIFs. Verify the specific vehicle and registration before investing.
Current signal
Advent’s India page and portfolio story document the 2024 sale of Bharat Serums and Vaccines to Mankind after operational improvements, including a reported EBITDA uplift during ownership; the India team page remains current with Shweta Jalan identified as Managing Partner.
Investor questions
Advent International (India) is covered in Rupeia's private equity research universe. The current public record describes the strategy as Buyout, with a sector focus of Health, pharma, fin services, industrial. The profile should be read with the linked source trail and Typical route: Category II AIF context.
The profile displays only company or asset names attributable to Advent International (India) in the reviewed public sources: Suven Pharma (control), Bharat Serums (exit to Mankind), Cohance/Suven merger, Manjushree (exit), Aditya Birla Capital stake. It does not represent a complete current portfolio unless the manager has published one.
Advent says its India team has completed more than 20 private-equity investments over 19 years. Its BSV case study reports a 20% EBITDA uplift during ownership and a sale to Mankind in 2024; the reviewed sources do not disclose India fund-level IRR or DPI. These signals are not a substitute for fund- and vintage-specific net performance, realised distributions and audited or administrator-supported reporting.
Public fund size: GPE X was reported at $25B globally; no current India-only fund size is disclosed. The GP’s India page reports more than 20 investments rather than a separate India AUM figure.. Public terms or access information: Control and complex growth investments across consumer, lending, manufacturing, pharmaceuticals and technology services. India cheque sizes and reserve policy are not consistently disclosed.. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.
The current source record names Shweta Jalan (India head). Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.
Review entry valuation, leverage, governance rights, concentration, execution of the value-creation plan and exit timing. The current open diligence point is: India-specific deployment total.
2024: Advent’s India page and portfolio story document the 2024 sale of Bharat Serums and Vaccines to Mankind after operational improvements, including a reported EBITDA uplift during ownership; the India team page remains current with Shweta Jalan identified as Managing Partner.
Next step
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.